Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Biological: filgrastimDrug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: etoposideDrug: ifosfamideDrug: imatinib mesylateDrug: leucovorin calciumDrug: mercaptopurine tabletDrug: methotrexateDrug: pegaspargaseDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationProcedure: peripheral blood stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 220
- Registration Number
- NCT00022737
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- EBMT Solid Tumors Working Party
- Target Recruit Count
- 460
- Registration Number
- NCT00005589
- Locations
- 🇩🇪
Universitaetsklinikum Goettingen, Goettingen, Germany
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1076
- Registration Number
- NCT00005596
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 838
- Registration Number
- NCT00005585
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 47
- Registration Number
- NCT00028899
- Locations
- 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸CancerCare of Maine at Eastern Maine Medial Center, Bangor, Maine, United States
🇺🇸Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, United States
Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 350
- Registration Number
- NCT00015873
- Locations
- 🇮🇹
Ospedale San Gerardo, Monza, Italy
🇳🇱Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
🇬🇧Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- European Working Group of MDS in Childhood
- Registration Number
- NCT00047268
- Locations
- 🇩🇪
Universitaetskinderklinik - Universitaetsklinikum Freiburg, Freiburg, Germany
Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- German Low Grade Lymphoma Study Group
- Registration Number
- NCT00016887
- Locations
- 🇧🇪
AZ Sint-Jan, Brugge, Belgium
🇮🇹Ospedale Civile Alessandria, Alessandria, Italy
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
- Target Recruit Count
- 60
- Registration Number
- NCT00028847
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪AZ Sint-Jan, Brugge, Belgium
🇳🇱Medisch Spectrum Twente, Enschede, Netherlands
Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
- Target Recruit Count
- 340
- Registration Number
- NCT00012051
- Locations
- 🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱HagaZiekenhuis - Locatie Leyenburg, 's-Gravenhage, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.